Kite is working with HiFiBiO Therapeutics to develop technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of various cancers, including solid tumours.
The companies intend to adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will potentially allow for the in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.
Neoantigens arise from tumour-specific mutations that are unique to each patient’s cancer, offering the potential for more targeted antitumor activity.
HiFiBiO will receive a $10 million upfront payment and will be eligible for additional payments based on the achievement of certain research milestones.
Kite will have an exclusive option to license HiFiBiO’s platform to screen T cell repertoires and to identify TCRs for use in TCR engineered T cell therapies with a corresponding payment to HiFiBiO.
“Neoantigen-based cell therapy is a very exciting, yet complex, area of research that has the potential to transform the way we treat many solid tumours,” said Alessandro Riva, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy.
“We are excited about this collaboration with HiFiBiO, which will build upon our existing capabilities focused on discovering cell therapies which target patient-specific tumour neoantigens.”